Lancet neurology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
Traumatic brain injury is a major cause of death and disability. We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury. ⋯ Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury.